https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/660376/az-bms-rumors-replimune-psychedelics-a-biocentury-podcasthttps://www.biocentury.com/article/660376/az-bms-rumors-replimune-psychedelics-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSAZ-BMS RUMORS, REPLIMUNE, PSYCHEDELICS — A BIOCENTURY PODCASTBioCentury’s analysts on mega-merger skepticism, regulatory roller-coasters, and psychedelics’ next frontier in depressionMon, 03 Aug 2026 17:37:26 -0700https://www.biocentury.com/article/660381/az-investors-aren-t-buying-it-neither-am-ihttps://www.biocentury.com/article/660381/az-investors-aren-t-buying-it-neither-am-i?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYAZ INVESTORS AREN’T BUYING IT — NEITHER AM IIt’s hard to see any strategic sense in the rumored merger of AstraZeneca and Bristol Myers: a PerspectiveMon, 03 Aug 2026 17:31:32 -0700https://www.biocentury.com/article/660371/radiopharmas-join-up-in-curium-lantheus-deal-deals-reporthttps://www.biocentury.com/article/660371/radiopharmas-join-up-in-curium-lantheus-deal-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSRADIOPHARMAS JOIN UP IN CURIUM, LANTHEUS DEAL: DEALS REPORTPlus: Supernus, Indivior merging complementary CNS portfolios; J&J/Sail; and moreMon, 03 Aug 2026 16:38:31 -0700https://www.biocentury.com/article/660375/litfulo-delivers-in-vitiligo-as-xpovio-misses-in-endometrial-cancerhttps://www.biocentury.com/article/660375/litfulo-delivers-in-vitiligo-as-xpovio-misses-in-endometrial-cancer?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTLITFULO DELIVERS IN VITILIGO AS XPOVIO MISSES IN ENDOMETRIAL CANCERBioCentury’s Clinical Report for July 28 – Aug. 3Mon, 03 Aug 2026 14:43:27 -0700https://www.biocentury.com/article/660346/mapping-the-psychedelics-frontier-in-depressionhttps://www.biocentury.com/article/660346/mapping-the-psychedelics-frontier-in-depression?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMAPPING THE PSYCHEDELICS FRONTIER IN DEPRESSIONLate-stage wins, pharma deals, and commercial precedent set the stage for psychedelics approvals within the next yearMon, 03 Aug 2026 14:29:25 -0700https://www.biocentury.com/article/660358/replimune-bounces-back-on-fda-panel-votehttps://www.biocentury.com/article/660358/replimune-bounces-back-on-fda-panel-vote?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEREPLIMUNE BOUNCES BACK ON FDA PANEL VOTEAdvisory committee supports RP1 despite negative briefing docsFri, 31 Jul 2026 16:20:43 -0700https://www.biocentury.com/article/660338/spot-bio-delivering-full-length-genes-to-muscle-without-viruseshttps://www.biocentury.com/article/660338/spot-bio-delivering-full-length-genes-to-muscle-without-viruses?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILESPOT BIO: DELIVERING FULL-LENGTH GENES TO MUSCLE WITHOUT VIRUSESExtracellular vesicle-delivered DMD gene therapy enters investigator-led testing, with ischemic injury nextFri, 31 Jul 2026 16:03:44 -0700https://www.biocentury.com/article/660340/apnimed-gains-in-aftermarket-as-three-biotechs-outline-ipo-aims-finance-reporthttps://www.biocentury.com/article/660340/apnimed-gains-in-aftermarket-as-three-biotechs-outline-ipo-aims-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEAPNIMED GAINS IN AFTERMARKET AS THREE BIOTECHS OUTLINE IPO AIMS: FINANCE REPORTBraveheart, Attovia, Vogenx could be next to reach NASDAQ; plus, Yarrow’s PIPE, Claris’ nine-figure venture round; and moreFri, 31 Jul 2026 14:43:34 -0700https://www.biocentury.com/article/660332/ai-biotechs-punched-above-their-weight-in-1h26-venture-megaroundshttps://www.biocentury.com/article/660332/ai-biotechs-punched-above-their-weight-in-1h26-venture-megarounds?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEAI BIOTECHS PUNCHED ABOVE THEIR WEIGHT IN 1H26 VENTURE MEGAROUNDSAI biotech financings were three times as likely to top $200M, even as the category’s median round trailed non-AI biotechsThu, 30 Jul 2026 17:38:48 -0700https://www.biocentury.com/article/660351/antisense-pioneer-bennett-to-retirehttps://www.biocentury.com/article/660351/antisense-pioneer-bennett-to-retire?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSANTISENSE PIONEER BENNETT TO RETIREPlus: J&J vet Rooney joins Kymera, Weiner-Trapness now executive chair of Allergy, Recursion co-founder Gibson becomes partner at DimensionThu, 30 Jul 2026 17:36:17 -0700https://www.biocentury.com/article/660341/with-sail-deal-j-j-becomes-latest-pharma-to-pursue-multiple-in-vivo-car-t-approacheshttps://www.biocentury.com/article/660341/with-sail-deal-j-j-becomes-latest-pharma-to-pursue-multiple-in-vivo-car-t-approaches?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTWITH SAIL DEAL, J&J BECOMES LATEST PHARMA TO PURSUE MULTIPLE IN VIVO CAR T APPROACHESJ&J’s $785M deal with Flagship’s Sail adds circular RNA to its existing lentiviral strategyThu, 30 Jul 2026 16:33:48 -0700https://www.biocentury.com/article/660312/fda-s-august-pdufas-revisit-rejectionshttps://www.biocentury.com/article/660312/fda-s-august-pdufas-revisit-rejections?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEFDA’S AUGUST PDUFAS REVISIT REJECTIONSAt least two of 11 decisions involve CBER-regulated products that have encountered setbacks. Capricor suffered another WednesdayWed, 29 Jul 2026 17:22:48 -0700https://www.biocentury.com/article/660326/science-spotlight-htt-variant-increases-risk-for-fibromyalgiahttps://www.biocentury.com/article/660326/science-spotlight-htt-variant-increases-risk-for-fibromyalgia?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: HTT VARIANT INCREASES RISK FOR FIBROMYALGIABioCentury’s roundup of translational innovations also includes engineering bacteria for cancerWed, 29 Jul 2026 16:23:09 -0700https://www.biocentury.com/article/660328/caldera-draws-278m-in-pipe-finds-quick-path-from-newco-to-nasdaqhttps://www.biocentury.com/article/660328/caldera-draws-278m-in-pipe-finds-quick-path-from-newco-to-nasdaq?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCECALDERA DRAWS $278M IN PIPE, FINDS QUICK PATH FROM NEWCO TO NASDAQThe deal will fund mid-stage development of a bispecific that could improve on ‘efficacy ceiling’ of existing therapies for inflammatory bowel diseaseWed, 29 Jul 2026 13:37:41 -0700https://www.biocentury.com/article/660298/biotechs-entering-the-ranks-of-billion-plus-buyershttps://www.biocentury.com/article/660298/biotechs-entering-the-ranks-of-billion-plus-buyers?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSBIOTECHS ENTERING THE RANKS OF BILLION-PLUS BUYERSMid- to large-cap biotechs are making up a growing share of $1B+ takeoutsTue, 28 Jul 2026 17:02:15 -0700https://www.biocentury.com/article/660279/bionyra-pairing-longer-lived-antibodies-with-emerging-i-i-targetshttps://www.biocentury.com/article/660279/bionyra-pairing-longer-lived-antibodies-with-emerging-i-i-targets?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEBIONYRA: PAIRING LONGER-LIVED ANTIBODIES WITH EMERGING I&I TARGETSTransatlantic biotech launched last month with $165M series A round to advance three in-licensed antibodiesTue, 28 Jul 2026 16:42:58 -0700https://www.biocentury.com/article/660319/b7-h3-promise-builds-in-underserved-cancershttps://www.biocentury.com/article/660319/b7-h3-promise-builds-in-underserved-cancers?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTB7-H3 PROMISE BUILDS IN UNDERSERVED CANCERSHansoh reports Phase III PFS win for risvutatug rezetecan in osteosarcomaTue, 28 Jul 2026 15:53:19 -0700https://www.biocentury.com/article/660317/fda-built-advisory-committee-around-replimune-controversieshttps://www.biocentury.com/article/660317/fda-built-advisory-committee-around-replimune-controversies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA BUILT ADVISORY COMMITTEE AROUND REPLIMUNE CONTROVERSIESTemporary members bring melanoma, trial design, radiology experience to assess twice-rejected RP1Tue, 28 Jul 2026 15:10:18 -0700https://www.biocentury.com/article/660301/ceos-departing-legend-sareptahttps://www.biocentury.com/article/660301/ceos-departing-legend-sarepta?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSCEOS DEPARTING LEGEND, SAREPTAVallance to chair U.K.’s new AI task forceMon, 27 Jul 2026 16:27:46 -0700https://www.biocentury.com/article/660296/argenx-m-a-ai-giants-in-biopharma-catalyst-scorecard-a-biocentury-podcasthttps://www.biocentury.com/article/660296/argenx-m-a-ai-giants-in-biopharma-catalyst-scorecard-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSARGENX M&A, AI GIANTS IN BIOPHARMA, CATALYST SCORECARD — A BIOCENTURY PODCASTThe $2B takeout of Forte, mapping AI moves in biopharma, and 1H26 clinical wins and lossesMon, 27 Jul 2026 16:20:54 -0700https://www.biocentury.com/article/660294/spac-reverse-merger-take-oak-hill-scancell-to-nasdaqhttps://www.biocentury.com/article/660294/spac-reverse-merger-take-oak-hill-scancell-to-nasdaq?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSSPAC, REVERSE MERGER TAKE OAK HILL, SCANCELL TO NASDAQBioCentury’s Deals Report, July 21-27Mon, 27 Jul 2026 16:07:01 -0700https://www.biocentury.com/article/660292/maplight-falls-as-once-daily-arm-of-cobenfy-rival-misses-in-schizophreniahttps://www.biocentury.com/article/660292/maplight-falls-as-once-daily-arm-of-cobenfy-rival-misses-in-schizophrenia?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMAPLIGHT FALLS AS ONCE-DAILY ARM OF COBENFY RIVAL MISSES IN SCHIZOPHRENIABioCentury’s Clinical Report, July 21–27Mon, 27 Jul 2026 15:43:08 -0700https://www.biocentury.com/article/660284/argenx-enters-biotech-buyer-class-with-2-2b-forte-takeouthttps://www.biocentury.com/article/660284/argenx-enters-biotech-buyer-class-with-2-2b-forte-takeout?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSARGENX ENTERS BIOTECH BUYER CLASS WITH $2.2B FORTE TAKEOUTVyvgart’s growth powers argenx’s first acquisition, adding anti-CD122 mAb FB102 as its next potential pipeline-in-a-productMon, 27 Jul 2026 14:39:42 -0700https://www.biocentury.com/article/660280/song-among-trio-of-new-partners-at-venrockhttps://www.biocentury.com/article/660280/song-among-trio-of-new-partners-at-venrock?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSSONG AMONG TRIO OF NEW PARTNERS AT VENROCKPlus: Moves at Roche, Sanofi and moreFri, 24 Jul 2026 17:14:12 -0700https://www.biocentury.com/article/660252/hub-101-taiwan-biotech-looks-to-level-uphttps://www.biocentury.com/article/660252/hub-101-taiwan-biotech-looks-to-level-up?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYHUB 101: TAIWAN BIOTECH LOOKS TO LEVEL UPFour companies show how Taiwan is combining global ambition, local capital, and technology strengths to build a biotech hubFri, 24 Jul 2026 16:57:15 -0700https://www.biocentury.com/article/660256/ema-s-chmp-backs-two-orphan-drugs-rebuffs-fda-approved-npc-therapyhttps://www.biocentury.com/article/660256/ema-s-chmp-backs-two-orphan-drugs-rebuffs-fda-approved-npc-therapy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONEMA’S CHMP BACKS TWO ORPHAN DRUGS, REBUFFS FDA-APPROVED NPC THERAPYAmong eight positive opinions, Minoryx’s cALD therapy wins backing after a 2024 rejectionFri, 24 Jul 2026 16:54:54 -0700https://www.biocentury.com/article/660277/scribe-extends-run-of-strong-biotech-ipo-debuts-public-equity-reporthttps://www.biocentury.com/article/660277/scribe-extends-run-of-strong-biotech-ipo-debuts-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCESCRIBE EXTENDS RUN OF STRONG BIOTECH IPO DEBUTS: PUBLIC EQUITY REPORTPlus: PIPEs for reverse mergers as Mentari, Freenome reach NASDAQ; Dyne’s follow-on; and moreFri, 24 Jul 2026 13:53:50 -0700https://www.biocentury.com/article/660067/mapping-ai-giants-bets-across-the-biopharma-tech-stackhttps://www.biocentury.com/article/660067/mapping-ai-giants-bets-across-the-biopharma-tech-stack?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONMAPPING AI GIANTS’ BETS ACROSS THE BIOPHARMA TECH STACKA guide to how recent releases from Anthropic, NVIDIA, Google, OpenAI and Amazon fit into biopharma R&D workflows — and with one anotherThu, 23 Jul 2026 17:57:34 -0700https://www.biocentury.com/article/660221/science-spotlight-host-directed-antivirals-and-a-bivalent-molecular-gluehttps://www.biocentury.com/article/660221/science-spotlight-host-directed-antivirals-and-a-bivalent-molecular-glue?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: HOST-DIRECTED ANTIVIRALS AND A BIVALENT MOLECULAR GLUEBioCentury’s roundup of translational innovations Thu, 23 Jul 2026 17:19:58 -0700https://www.biocentury.com/article/660243/crossovers-join-crystalys-130m-series-b-venture-reporthttps://www.biocentury.com/article/660243/crossovers-join-crystalys-130m-series-b-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCECROSSOVERS JOIN CRYSTALYS’ $130M SERIES B: VENTURE REPORTPlus: New spinout Synaptiq addresses rare neuropsychiatric disease; Dimension’s new fund; and moreThu, 23 Jul 2026 16:48:02 -0700https://www.biocentury.com/article/660225/dosing-liver-profile-may-differentiate-arrowhead-in-severe-hypertriglyceridemiahttps://www.biocentury.com/article/660225/dosing-liver-profile-may-differentiate-arrowhead-in-severe-hypertriglyceridemia?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTDOSING, LIVER PROFILE MAY DIFFERENTIATE ARROWHEAD IN SEVERE HYPERTRIGLYCERIDEMIAPhase III data suggest little differentiation in efficacy versus Ionis’ Tryngolza, but Redemplo could offer advantages in dosing and hepatic safetyThu, 23 Jul 2026 11:36:16 -0700https://www.biocentury.com/article/660203/initiate-s-owens-on-early-funding-and-what-it-takes-to-be-ai-nativehttps://www.biocentury.com/article/660203/initiate-s-owens-on-early-funding-and-what-it-takes-to-be-ai-native?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEINITIATE’S OWENS ON EARLY FUNDING AND WHAT IT TAKES TO BE AI-NATIVEFounding Partner Jessica Owens details firm’s strategy, how proprietary data beats proprietary models, and gaps in evidence generation: The BioCentury ShowWed, 22 Jul 2026 17:31:13 -0700https://www.biocentury.com/article/660192/former-black-diamond-ceo-david-epstein-passes-awayhttps://www.biocentury.com/article/660192/former-black-diamond-ceo-david-epstein-passes-away?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSFORMER BLACK DIAMOND CEO DAVID EPSTEIN PASSES AWAYCareer spanned three decades in biotechWed, 22 Jul 2026 14:34:00 -0700https://www.biocentury.com/article/660222/wuxi-apptec-s-injunction-may-hinge-on-irreparable-harmhttps://www.biocentury.com/article/660222/wuxi-apptec-s-injunction-may-hinge-on-irreparable-harm?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWUXI APPTEC’S INJUNCTION MAY HINGE ON ‘IRREPARABLE HARM’At oral arguments, judge seemed to lean toward WuXi AppTec on some issues, but didn’t tip his hand on a critical questionWed, 22 Jul 2026 13:40:19 -0700https://www.biocentury.com/article/660209/the-next-50-years-won-t-be-defined-by-bordershttps://www.biocentury.com/article/660209/the-next-50-years-won-t-be-defined-by-borders?utm_source=bc_rss&utm_medium=rssBIOCENTURY | BIOCENTURY COMMENTARYTHE NEXT 50 YEARS WON’T BE DEFINED BY BORDERSGeography is becoming a less reliable guide to where important science originates, but translating it across borders demands judgment and disciplined execution Wed, 22 Jul 2026 10:38:32 -0700https://www.biocentury.com/article/660159/2026-catalysts-first-half-scorecardhttps://www.biocentury.com/article/660159/2026-catalysts-first-half-scorecard?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENT2026 CATALYSTS: FIRST-HALF SCORECARDRNA, other new modalities and cardiorenal programs largely delivered in 1H26, despite uneven antisense performanceTue, 21 Jul 2026 18:36:47 -0700https://www.biocentury.com/article/660211/series-a-rounds-grew-larger-as-deal-count-fell-in-1h26https://www.biocentury.com/article/660211/series-a-rounds-grew-larger-as-deal-count-fell-in-1h26?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTESERIES A ROUNDS GREW LARGER AS DEAL COUNT FELL IN 1H26Median series A size rose to a decade high of $29.1M as the first-half tally hit a 10-year low; Forbion, Qiming and RA Capital led activityTue, 21 Jul 2026 16:51:26 -0700https://www.biocentury.com/article/660215/ipo-queue-swells-as-scribe-aims-to-price-this-weekhttps://www.biocentury.com/article/660215/ipo-queue-swells-as-scribe-aims-to-price-this-week?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEIPO QUEUE SWELLS AS SCRIBE AIMS TO PRICE THIS WEEKLatigo, BlossomHill among those joining the list of biotechs seeking to go public on NASDAQTue, 21 Jul 2026 13:22:42 -0700https://www.biocentury.com/article/660194/u-k-cabinet-shuffle-taiwan-biotech-and-biogen-data-a-biocentury-podcasthttps://www.biocentury.com/article/660194/u-k-cabinet-shuffle-taiwan-biotech-and-biogen-data-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWU.K. CABINET SHUFFLE, TAIWAN BIOTECH AND BIOGEN DATA — A BIOCENTURY PODCASTPlus: Lilly’s psychedelic play and what’s new at FDAMon, 20 Jul 2026 19:08:47 -0700https://www.biocentury.com/article/660187/with-syndicate-investing-132m-jasper-merging-with-kira-deals-reporthttps://www.biocentury.com/article/660187/with-syndicate-investing-132m-jasper-merging-with-kira-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSWITH SYNDICATE INVESTING $132M, JASPER MERGING WITH KIRA: DEALS REPORTPlus: TempusAI buys Personalis; Bora/Insilico; AZ/Dizal; and moreMon, 20 Jul 2026 17:49:47 -0700https://www.biocentury.com/article/660196/wuxi-apptec-says-1260h-listing-based-on-demonstrably-false-assertionshttps://www.biocentury.com/article/660196/wuxi-apptec-says-1260h-listing-based-on-demonstrably-false-assertions?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWUXI APPTEC SAYS 1260H LISTING BASED ON ‘DEMONSTRABLY FALSE’ ASSERTIONSChinese CDMO says DoD wildly overstated Chinese government fund’s stakeMon, 20 Jul 2026 17:00:58 -0700https://www.biocentury.com/article/660189/science-minister-vallance-out-u-k-biotech-s-latest-body-blowhttps://www.biocentury.com/article/660189/science-minister-vallance-out-u-k-biotech-s-latest-body-blow?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWSCIENCE MINISTER VALLANCE OUT — U.K. BIOTECH’S LATEST BODY BLOWHealey as Chancellor seen as good choice, but future of life science policy could go either wayMon, 20 Jul 2026 14:32:34 -0700https://www.biocentury.com/article/660185/axiom-s-newborn-survival-signal-gsk-s-chronic-cough-setback-and-morehttps://www.biocentury.com/article/660185/axiom-s-newborn-survival-signal-gsk-s-chronic-cough-setback-and-more?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTAXIOM’S NEWBORN SURVIVAL SIGNAL, GSK’S CHRONIC COUGH SETBACK, AND MOREBioCentury’s Clinical Report July 14 – 20Mon, 20 Jul 2026 14:15:38 -0700https://www.biocentury.com/article/660154/hdrs-launches-as-a-single-front-door-to-u-k-health-datahttps://www.biocentury.com/article/660154/hdrs-launches-as-a-single-front-door-to-u-k-health-data?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONHDRS LAUNCHES AS A SINGLE FRONT DOOR TO U.K. HEALTH DATAThe U.K. is extending its data offering to researchers far beyond the UK Biobank, with a system that integrates all NHS data across the whole nationMon, 20 Jul 2026 12:30:53 -0700https://www.biocentury.com/article/660172/seed-and-series-a-financing-lagged-biotech-s-broader-recovery-in-1h26https://www.biocentury.com/article/660172/seed-and-series-a-financing-lagged-biotech-s-broader-recovery-in-1h26?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTESEED AND SERIES A FINANCING LAGGED BIOTECH’S BROADER RECOVERY IN 1H26Early-stage round count fell to a decade low and capital dropped 15%, even as total venture dollars rose 22%Fri, 17 Jul 2026 17:09:55 -0700https://www.biocentury.com/article/660155/peptides-rp1-advisory-committees-will-test-fda-s-credibilityhttps://www.biocentury.com/article/660155/peptides-rp1-advisory-committees-will-test-fda-s-credibility?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONPEPTIDES, RP1 ADVISORY COMMITTEES WILL TEST FDA’S CREDIBILITYSeven compounding panel members have ties to peptide businesses; RP1 roster remains undisclosedFri, 17 Jul 2026 15:43:14 -0700https://www.biocentury.com/article/660169/fda-uses-informal-channel-to-disavow-makary-s-informal-policy-pronouncementshttps://www.biocentury.com/article/660169/fda-uses-informal-channel-to-disavow-makary-s-informal-policy-pronouncements?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA USES INFORMAL CHANNEL TO DISAVOW MAKARY’S INFORMAL POLICY PRONOUNCEMENTSActing commissioner’s unreleased letter to Rep. DeGette leaves drug companies, investors and patients in a quandaryFri, 17 Jul 2026 14:38:26 -0700https://www.biocentury.com/article/660168/more-biotechs-queue-up-to-go-public-public-equity-reporthttps://www.biocentury.com/article/660168/more-biotechs-queue-up-to-go-public-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEMORE BIOTECHS QUEUE UP TO GO PUBLIC: PUBLIC EQUITY REPORTPlus: Erasca raises $632.5M follow-on to accelerate pivotal trials of RAS inhibitorFri, 17 Jul 2026 11:05:24 -0700https://www.biocentury.com/article/660148/biotech-drew-more-venture-dollars-in-1h26-as-deal-count-stayed-leanhttps://www.biocentury.com/article/660148/biotech-drew-more-venture-dollars-in-1h26-as-deal-count-stayed-lean?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEBIOTECH DREW MORE VENTURE DOLLARS IN 1H26 AS DEAL COUNT STAYED LEANMedian round size neared a record, while 14 megarounds accounted for $6.1 billion, nearly a third of all capital raisedThu, 16 Jul 2026 17:08:49 -0700https://www.biocentury.com/article/660130/roche-bets-on-divarasib-superiority-while-advancing-pan-ras-inhibitorshttps://www.biocentury.com/article/660130/roche-bets-on-divarasib-superiority-while-advancing-pan-ras-inhibitors?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTROCHE BETS ON DIVARASIB SUPERIORITY WHILE ADVANCING PAN-RAS INHIBITORSHead-to-head NSCLC win strengthens the next-generation G12C inhibitor’s position against Lumakras and KrazatiThu, 16 Jul 2026 17:03:53 -0700